oligodendroglioma (Cancer)
Information
- Disease name
- oligodendroglioma
- Disease ID
- DOID:3181
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03180502 | Active, not recruiting | Phase 2 | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma | August 2, 2017 | January 2030 |
| NCT02549833 | Active, not recruiting | Phase 1 | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | October 17, 2016 | August 31, 2024 |
| NCT00165360 | Completed | Phase 2 | Prolonged Daily Temozolomide for Low-Grade Glioma | September 2001 | September 2009 |
| NCT01609790 | Completed | Phase 2 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | June 4, 2012 | May 20, 2022 |
| NCT00080054 | Completed | Phase 1 | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | ||
| NCT00392171 | Completed | Phase 2 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | June 9, 2006 | September 15, 2009 |
| NCT00575887 | Completed | Phase 2 | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma | August 2006 | March 2009 |
| NCT00717210 | Completed | Phase 3 | Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide | June 1999 | March 2008 |
| NCT00874861 | Completed | Early Phase 1 | HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas | April 2009 | November 2013 |
| NCT00009035 | Completed | Natural History of Patients With Brain and Spinal Cord Tumors | January 22, 2001 | September 11, 2018 | |
| NCT02530320 | Completed | Phase 2 | Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved | October 25, 2015 | March 2020 |
| NCT02747407 | Completed | Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors | May 2016 | September 9, 2021 | |
| NCT02871843 | Completed | Phase 1 | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas | February 14, 2017 | September 19, 2021 |
| NCT02903784 | Completed | N/A | Neural Basis of Language Processing | September 2012 | September 2016 |
| NCT03900689 | Completed | Social Determinants of Health in Glioblastoma Population | May 22, 2019 | March 27, 2022 | |
| NCT06439420 | Not yet recruiting | Phase 2 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial | July 1, 2024 | November 30, 2026 |
| NCT06241391 | Not yet recruiting | N/A | Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas | February 2024 | February 2025 |
| NCT05513859 | Not yet recruiting | N/A | Investigational Imaging Technique During Brain Surgery | June 30, 2024 | June 23, 2025 |
| NCT06161974 | Not yet recruiting | Phase 2 | Study of Olutasidenib and Temozolomide in HGG | June 2024 | June 2035 |
| NCT06038760 | Recruiting | Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO) | October 12, 2023 | December 1, 2025 | |
| NCT05331521 | Recruiting | Phase 3 | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). | April 7, 2021 | March 31, 2029 |
| NCT01849952 | Recruiting | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas | February 28, 2020 | May 2024 | |
| NCT02372409 | Recruiting | Phase 2 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | August 14, 2015 | August 31, 2030 |
| NCT05956821 | Recruiting | Phase 1/Phase 2 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | August 1, 2024 | December 1, 2029 |
| NCT03152318 | Recruiting | Phase 1 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | July 18, 2017 | December 2025 |
| NCT03796273 | Recruiting | Early Phase 1 | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases | March 13, 2019 | September 2024 |
| NCT04047264 | Recruiting | N/A | Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies | January 1, 2020 | September 1, 2027 |
| NCT04304300 | Recruiting | Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes | December 10, 2019 | May 2026 | |
| NCT04541082 | Recruiting | Phase 1 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | October 26, 2020 | February 2025 |
| NCT04623931 | Recruiting | Phase 2 | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | January 30, 2020 | December 31, 2026 |
| NCT04648462 | Recruiting | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | January 1, 2018 | January 1, 2035 | |
| NCT04702581 | Recruiting | Phase 3 | A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery | December 7, 2021 | December 2030 |
| NCT05190172 | Recruiting | N/A | PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas | January 14, 2022 | December 31, 2041 |
| NCT01649830 | Recruiting | Phase 3 | Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma | July 2012 | August 2026 |
| NCT05345002 | Recruiting | Phase 2 | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | November 16, 2022 | June 1, 2027 |
| NCT05512351 | Recruiting | Phase 2 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma | December 23, 2022 | December 2026 |
| NCT05561374 | Recruiting | Phase 1 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma | April 17, 2023 | August 15, 2024 |
| NCT05624736 | Recruiting | Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning | November 20, 2022 | May 1, 2025 | |
| NCT02924038 | Terminated | Phase 1 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | April 3, 2017 | December 31, 2022 |
| NCT00360828 | Terminated | Phase 2 | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas | February 2006 | October 2010 |
| NCT00389090 | Terminated | Phase 2 | A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma | October 2006 | February 2009 |
| NCT02764151 | Terminated | Phase 1 | First in Patient Study for PF-06840003 in Malignant Gliomas | September 9, 2016 | December 26, 2018 |
| NCT00031538 | Terminated | Genetic Analysis of Brain Tumors | March 1, 2002 | April 29, 2015 | |
| NCT01836549 | Terminated | Phase 2 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | March 2013 | April 2016 |
| NCT00035373 | Terminated | Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols | April 19, 2002 | April 29, 2015 | |
| NCT01089244 | Unknown status | FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma | June 2008 | December 2015 | |
| NCT03896958 | Unknown status | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) | March 21, 2019 | March 12, 2024 | |
| NCT02209428 | Unknown status | Phase 2 | A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas | June 2014 | May 2019 |
| NCT00591058 | Unknown status | Phase 1 | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | February 2008 | February 2010 |
| NCT00683761 | Unknown status | Phase 1/Phase 2 | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma | August 2008 | April 2010 |
| NCT04843085 | Unknown status | Proteomic Characterization of Aggressive Oligodendrogliomas | September 30, 2020 | September 2023 | |
| NCT04970615 | Unknown status | Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models | May 15, 2021 | December 15, 2023 | |
| NCT04105374 | Withdrawn | Phase 2/Phase 3 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | January 31, 2020 | November 30, 2030 |
| NCT02976441 | Withdrawn | Early Phase 1 | Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas | January 2017 | February 2018 |
| NCT03014804 | Withdrawn | Phase 2 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | December 1, 2019 | December 1, 2022 |
| NCT03353896 | Withdrawn | N/A | NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | December 15, 2017 | December 8, 2020 |
| NCT03649464 | Withdrawn | Phase 1/Phase 2 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | August 2022 | August 2025 |
- Disase is a (Disease Ontology)
- DOID:3070
- Cross Reference ID (Disease Ontology)
- GARD:9953
- Cross Reference ID (Disease Ontology)
- ICDO:9450/3
- Cross Reference ID (Disease Ontology)
- MESH:D009837
- Cross Reference ID (Disease Ontology)
- NCI:C3288
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0751396
- Exact Synonym (Disease Ontology)
- oligodendroglial neoplasm
- Exact Synonym (Disease Ontology)
- oligodendroglial tumor
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009837